Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

481.48 -2.67 (-0.55%)

Streaming Delayed Price Updated: 12:06 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

69 70 Next >

3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold ↗

April 22, 2025

Via The Motley Fool

Topics Government

Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts ↗

April 22, 2025

Via Benzinga

Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right ↗

April 22, 2025

Via The Motley Fool

Topics Economy Government World Trade

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely ↗

April 21, 2025

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises.

Via Benzinga

Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next ↗

April 18, 2025

Via The Motley Fool

Topics Government World Trade

Peering Into Vertex Pharmaceuticals's Recent Short Interest ↗

April 17, 2025

Via Benzinga

As The Nasdaq 100 Index Crashes, Is It Safe To Buy The Dip? ↗

April 17, 2025

The Nasdaq 100 Index remains under pressure after forming a death cross pattern a few weeks ago. It has retreated to $18,257, down by over 17.8% from its highest point this year.

Via Talk Markets

Topics Stocks / Equities

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce ↗

April 15, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades ↗

April 12, 2025

Via The Motley Fool

Topics Artificial Intelligence Government Stocks

CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' ↗

April 11, 2025

CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation.

Via Benzinga

Topics Artificial Intelligence

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

April 11, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

April 11, 2025

Via The Motley Fool

We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is. ↗

April 10, 2025

Via The Motley Fool

Topics Economy Government World Trade

5 Top Growth Stocks to Buy in the Stock Market Sell-Off ↗

April 09, 2025

Via The Motley Fool

Topics Government

Is Vertex Pharmaceuticals Stock a Buy? ↗

April 08, 2025

Via The Motley Fool

These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue? ↗

April 07, 2025

A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited.

Via Benzinga

Topics Stocks World Trade

Vertex to Announce First Quarter 2025 Financial Results on May 5th

April 07, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' ↗

April 07, 2025

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Via Benzinga

2 Stocks to Buy if You're Worried About a Recession ↗

April 07, 2025

Via The Motley Fool

Topics Economy Government

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm ↗

April 06, 2025

Via The Motley Fool

Topics Earnings Economy Government

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right. ↗

April 04, 2025

Via The Motley Fool

Topics Economy Energy Government

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

April 03, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...

Via StockStory

Topics Artificial Intelligence

Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗

April 02, 2025

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

Via Stocktwits

Topics ETFs Government

Is Vertex Pharmaceuticals Gaining or Losing Market Support? ↗

April 01, 2025

Via Benzinga

Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews ↗

March 31, 2025

Via Benzinga

Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data ↗

March 31, 2025

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Via Benzinga

Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). ↗

March 29, 2025

Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout.

Via Chartmill

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.